...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Month 10

SF - I totally agree with your reliability statement SF.

Unfortunately all patients don't go the distance as much as we would like them to. It may have been a patient that was in the second or third cohort that is still with us today and not one from the first cohort, we just don't know. My very limited understanding is that they start the first cohort of a Phase I Trial with a very small dose and then increase the dose with each cohort. It may have taken just a little more of ZEN3694 to assist the patient in going the distance, again we just don't know.

I truly hope you are correct and I am misguided for the patients sake.

 

tada

Share
New Message
Please login to post a reply